RedHill Biopharma to Present at German Equity Forum 2020
13. November 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
04. November 2020 10:30 ET
|
RedHill Biopharma Ltd.
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
13. Oktober 2020 10:30 ET
|
RedHill Biopharma Ltd.
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential...
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
07. Oktober 2020 10:00 ET
|
RedHill Biopharma Ltd.
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 --The U.S. Phase 2...
Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib
22. September 2020 10:00 ET
|
RedHill Biopharma Ltd.
The ongoing global Phase 2/3 study with orally-administered opaganib in patients with severe COVID-19 is approved in Italy, the UK, Russia, Israel, Mexico and Brazil; 16 clinical sites initiated...
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
08. September 2020 08:30 ET
|
RedHill Biopharma Ltd.
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive...
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
03. September 2020 07:05 ET
|
RedHill Biopharma Ltd.
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered,...
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
27. August 2020 07:00 ET
|
RedHill Biopharma Ltd.
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and...
RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
06. August 2020 07:00 ET
|
RedHill Biopharma Ltd.
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites--The global Phase 2/3 study has been approved in Mexico, the UK and Russia...
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
30. Juli 2020 07:00 ET
|
RedHill Biopharma Ltd.
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and...